Sarepta Therapeutics (SRPT) stock drops 25% as the company reports a patient death linked to Elevidys, its gene therapy developed with Roche (RHHBY). Read more here.

Wall Street analysts were quick to downgrade Sarepta Therapeutics (NASDAQ:SRPT) on Monday as the company suspended its revenue guidance for 2025 following a second fatality linked to Elevidys, its ...

Shares of Sarepta Therapeutics closed down as much as 42% to hit a nine-year low of $18.30 on Monday after a second death of a male teenage patient who had received its gene therapy, Elevidys ...

A second patient has died following treatment with Sarepta Therapeutics’ Elevidys, raising more doubts about the Duchenne muscular dystrophy (DMD) gene therapy’s safety profile.

Sarepta management is predicting a significant uptick in use in the near future. Up until June, Elevidys was only available to certain boys with Duchenne who were 4 or 5 years old, capping its ...

Sarepta Therapeutics submitted a request to the FDA for label expansion of Elevidys, with a response expected by June 21st. Read why SRPT stock is a buy.

Teenager who received Elevidys, Sarepta’s Duchenne gene therapy, dies By Jason Mast STAT,Updated March 18, 2025, 2:50 p.m.

Following the expanded FDA approval in late June, Elevidys brought in $384 million sales for Sarepta during the last three months of 2024. During the prior quarter, sales were $181 million.